Energy News / Shareholders Foundation, Inc.

NASDAQ:MNLO Shareholder Notice: Investigation over Potential Wrongdoing at Menlo Therapeutics Inc

Via: ReleaseWire

Updated 11:15 AM CDT, Wed, September 19,2018

An investigation on behalf of investors in Menlo Therapeutics Inc. (NASDAQ: MNLO) shares over potential wrongdoing at Menlo Therapeutics Inc. was announced.

San Diego, CA -- (SBWIRE) -- 09/19/2018 -- An investigation was announced over whether Menlo Therapeutics Inc. (NASDAQ: MNLO) or certain of its officers and directors violated federal securities.

Investors who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Redwood City, CA based Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. Menlo Therapeutics Inc. went public in early 2018.

On April 9, 2018, Menlo Therapeutics Announces Results from a Phase 2 Trial of Serlopitant for Pruritus Associated with Atopic Dermatitis.

Menlo Therapeutics Inc disclosed that Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis failed to meet its primary or key secondary efficacy endpoints. The trial showed no statistically significant difference between patients treated with serlopitant and patients treated with placebo.

The investigation by a law firm concerns whether Menlo Therapeutics Inc's filings with the U.S. Securities and Exchange Commission in connection with the IPO contained untrue statements of material fact or omitted material information, specifically regarding the Company's second Phase 2 clinical trial of patients treated with serlopitant.

Those who purchased shares of Menlo Therapeutics Inc. (NASDAQ: MNLO), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqmnlo-shareholder-notice-investigation-over-potential-wrongdoing-at-menlo-therapeutics-inc-1049942.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com